Bob Azelby, Eliem CEO
April 25, 2022 08:57 AM EDT
Startups
R&D

'Re­sults are un­am­bigu­ous': Eliem's lead pro­gram fails and share price halves be­fore open­ing bell

Kyle LaHucik

Senior Reporter

When Eliem Ther­a­peu­tics launched last March, CSO Va­lerie Moris­set told End­points News that up­on be­ing ap­proached about mak­ing a leap to the biotech, she had …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times